首页|NIR-Ⅱb-triggered photodynamic therapy combined with chemotherapy platform based on rare-earth-doped nanoparticles

NIR-Ⅱb-triggered photodynamic therapy combined with chemotherapy platform based on rare-earth-doped nanoparticles

扫码查看
Photodynamic therapy(PDT),with high spa-tiotemporal selectivity,minimal side effects and less drug resistance,has emerged as a promising approach for the treatment of cancer.However,inadequate penetration depth and poor efficacy seriously restrict its practical application.To address these challenges,we developed a combined therapy platform(RENP@C/D-FA)based on rare-earth-doped nanoparticles(RENPs)with a structure of NaErF4∶Tm(0.5%)@NaYF4,on which photosensitizer Ce6(chlorin e6)and chemo-therapeutic drug(DOX)(doxoru-bicin)were loaded by encapsulating with an amphiphilic polymer distearoyl phosphatidylethanolamine-poly-ethylene glycol-folic acid(DSPE-PEG-FA).RENPs with NaErF4 as the matrix possess multiple excitation/emission peaks,enabling activation of PDT under near-infrared-Ⅱb(NIR-Ⅱb,1500-1700 nm)excitation and luminescence imaging in NIR-Ⅱb region by absorbing 808 nm near-in-frared photons.Furthermore,DOX can be selectively released in the acidic microenvironment of tumors.Bene-fiting from the tumor targeting capability of folic acid,this platform can successfully ablate tumor cells and inhibit tumor growth by combining PDT and chemotherapy.This innovative approach holds great promise as a powerful tool for cancer treatment,showing the potential to revolutionize PDT.

Photodynamic therapyRare-earth-doped nanoparticlesNIR-ⅡbChemotherapyCombined therapy

Zhuo Tu、Yong Wan、Juan Ge、Chen-Chen Li、Tao Liang、Zhen Li

展开 >

College of Health Science and Engineering,College of Chemistry and Chemical Engineering,Hubei University,Wuhan 430062,China

National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaHubei Province Outstanding Youth Foundation

22004133221740352022CFA082

2024

稀有金属(英文版)
中国有色金属学会

稀有金属(英文版)

CSTPCDEI
影响因子:0.801
ISSN:1001-0521
年,卷(期):2024.43(7)